Porton Pharma Solutions reports nine-month revenue growth of 8.66%
Regulatory / securities filing · 博腾股份 / 巨潮资讯 CNinfo
Source published: · Event / reporting date: 2026-09-30
Site published: 2026-11-03 · Updated: 2026-11-03
This source is linked automatically. Choose a question to get started.
What changed
Porton Pharma Solutions reported consolidated revenue of RMB2.765 billion, up 8.66%, and an attributable net loss of RMB112.1 million for the nine months ended September 30, 2026. The group posted an attributable loss of RMB112.1 million; impairment related to its discontinued Slovenia project affected earnings. The quarterly filing is unaudited and covers the year-to-date period.
Why it may matter
Separate asset impairment from ongoing order execution, and avoid treating the nine-month loss as the result for the third quarter alone.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections